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Chronic beryllium disease (CBD) begins as a sensitizing cell-mediated immune response to beryl-
lium antigen that progresses to granulomatous lung disease. Previous studies demonstrated the
involvement of proinflammatory cytokines in the disease process, but the pattern and regulation
of cytokine release is unknown. Using bronchoalveolar lavage (BAL) cells from CBD patients in
short-term tissue culture, we evaluated cytokine protein levels by enzyme-linked immunosorbent
assay and T-lymphocyte proliferation by tritiated thymidine incorporation. We observed the beryl-
lium-stimulated release of tumor necrosis factor-alpha (TNF-ix), interleukin-6 (IL-6), interleukin-2
(IL-2), and interferon-gamma (IFN-y) but not interleukin-4 (IL-4). Beryllium-stimulated IFN-y release
was sustained to 168 hr in culture, whereas IL-2 concentrations returned to baseline after 24 hr.
Neutralization of IL-2 decreased beryllium-stimulated T-lymphocyte proliferation, but the level of
proliferation remained elevated in comparison to unstimulated BAL cells. These data suggest that
T helper 1 (Thl) lymphocytes participate in the beryllium disease process; that IFN-y levels remain
elevated after IL-2 levels return to baseline; and that IL-2 participates directly in beryllium-stimu-
lated T-cell proliferation, but other T-lymphocyte mitogenic cytokines may be involved. Environ
Health Perspect 104(Suppl 5):969-971 (1996)
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Introduction
Chronic beryllium disease (CBD) is an
occupationally acquired lung disease with
clinical findings similar to those of other
granulomatous diseases such as sarcoidosis,
schistosomiasis, and tuberculosis. The dis-
ease process begins as a sensitizing cell-medi-
ated immune response to beryllium antigen
that, over time, results in the development
ofnoncaseating granulomas (1). An under-
standing ofthe cellular and molecular events
that underlie the transition from antigen sen-
sitization to disease may provide improved
markers of disease progression and earlier
opportunities for therapeutic intervention.
The antigen-specific inflammatory
response is a cell-mediated process orches-
trated by cytokines. These intracellular sig-
naling molecules form the feed-forward
and feed-back loops that initiate and then
attenuate the cell-mediated immune
response to antigen (Figure 1). In CBD, an
antigen-presenting cell (APC) presents
beryllium, most probably in conjunction
with a peptide, to a T lymphocyte in a
major histocompatibility complex (MHC)
class 1I-restricted process that results in
T-lymphocyte proliferation (2,3). Alveolar
macrophages and T lymphocytes, the
predominant cells found in the lungs of
beryllium-diseased individuals, are
thought to mediate the beryllium-specific
immune response (3). Previous studies of
cytokines in beryllium disease showed
that alveolar macrophages express elevated
levels ofmRNA for tumor necrosis factor-
alpha (TNF-x) and interleukin-6 (IL-6)
but not for interleukin-1 beta (IL-11) (4)
and that T-lymphocyte proliferation
involves increased levels of interleukin-2
(IL-2) and IL-2 receptor (1,3). These
studies confirm the role of cytokines in
the disorder but not the specific mecha-
nism by which cytokines participate in the
disease process.
We hypothesize that the addition of
beryllium salts to CBD-derived broncho-
alveolar (BAL) cells in vitro will stimulate
the release of proinflammatory cytokines
that drive granuloma formation and dis-
ease. For this study, we established an ex
vivo BAL cell system to evaluate beryllium-
stimulated release ofTNF-a and IL-6; the
T-helper 1 (Thl) cytokines, IL-2 and IFN-
y, and the T helper 2 (Th2) cytokine, IL-4.
To examine the interdependence of these
cytokines, we evaluated the effect of IL-2
neutralizing antibody on T-lymphocyte
proliferation and on release of TNF-a,
IL-6, and IFN-y.
Methods
In this study, we obtained BAL cells from
a nonexposed population (n=4) and from
patients with CBD (n= 5) by standard
lavage methods previously reported (5).
Informed consent was secured from all
participants prior to the procedure. Cells
were cultured at 1 x 106 cells/ml for up to
7 days under standard mammalian tissue
culture conditions in the presence or
absence of 100 pM BeSO4 and in the
presence and absence of titrated amounts
of antihuman IL-2 neutralizing antibody
(R&D Systems, Minneapolis, MN). The
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Figure 1. The proinflammatory cytokine network is a
complex, multicellular system represented in this
schema by an antigen-presenting cell, T lymphocytes,
and cytokines.
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Figure 2. Unstimulated and beryllium-stimulated
cytokine profiles from a normal volunteer (A) and a
CBD patient (B).
concentration of cytokines was measured
by enzyme-linked immunosorbent assay
(ELISA) (R&D Systems) and T-lymphocyte
proliferation was measured by tritiated
thymidine incorporation.
Results
Unstimulated cells and beryllium-stimulated
cells from nonexposed individuals released
low levels of the cytokines TNF-ax and
IL-6 but not the T-lymphocyte-associated
cytokines IL-2, IL-4, and IFN-y (Figure 2).
In the absence ofberyllium salts, BAL cells
from patients with CBD demonstrated cyto-
kine profiles similar to those observed in the
nonexposed population. However, beryl-
lium salts increased release ofTNF-a and
IL-6 from BAL cells ofberyllium-diseased
individuals. Supernatant concentrations of
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Figure 3. Neutralization of IL-2 in beryllium-stimulated
BAL cell cultures from a CBD patient decreased T-lym-
phocyte proliferation, as measured by tritiated thymi-
dine incorporation in a dose-dependent manner.
IL-2 and IFN-y also increased, but no
spontaneous or beryllium-stimulated
release of IL-4 was observed. IFN-y levels
remained elevated to 168 hr, whereas IL-2
levels peaked between 6 and 24 hr after the
addition ofberyllium salts and returned to
baseline by 48 hr.
Neutralization of IL-2 decreased
T-lymphocyte proliferation in a dose-
dependent manner (Figure 3). However,
complete neutralization of IL-2 did not
return the level ofberyllium-stimulated T-
lymphocyte proliferation to the levels
observed for unstimulated BAL cells in
four offive patients studied. Neutralization
of IL-2 did not alter TNF-cx and IL-6
release, but it did cause a decrease in the
concentration ofIFN-y (Figure 4).
Discussion
These studies suggest that this ex vivo cell
system allows us to evaluate the role of
cytokines in the beryllium-stimulated, cell-
mediated immune response through the
sequential and temporal manipulation of
the cytokine network. In CBD, there is
beryllium-stimulated release ofTNF-ox, IL-
6, IL-2, and IFN-,y. The T cell-associated
release of IL-2 and IFN-y but not IL-4 is
consistent with the Thl phenotype. And
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Figure 4. Neutralization of IL-2 decreased beryllium-
stimulated IFN-y release from BAL cells from a CBD
patient. Closed symbols=+100 lOM BeSO4; open
symbols=+100 ,uM BeSO4+0.5 ng IL-2 antibody/mi.
neutralizing antibody suggests a role for
other T-lymphocyte mitogenic cytokines.
The partial IL-2 dependence of IFN-y
release observed in this study is also found
in other cell systems (6,7). However, most
studies describe a parallel time course for
IL-2 and IFN-y in contrast to the sustained
release of IFN-y but not IL-2 observed in
our beryllium-stimulated BAL cell system.
Previous research on IFN-y indicates that
following mitogen stimulation in vitro,
both IL-2 and IFN-y protein levels peak at
about 20 to 24 hr and then return to base-
line (8,9) or, in antigen-driven diseases
such as schistosomiasis and leishmaniasis,
both IL-2 and IFN-y levels remain elevated
for 3 to 18 days (10-12). It is intriguing to
consider that IFN-'y drives the transition
from cell-mediated immune response to
granuloma formation and disease (Figure
1). IFN-,y upregulates macrophage-derived
cytokine production (13), increases expres-
sion of the MHC class II molecules (14),
and stimulates expansion of the Thl lym-
phocyte subsets (15)-all components of
the normal cell-mediated immune response
and the beryllium disease process. Studies
on the interdependence ofCBD-associated
cytokines are continuing, and extension of
these studies to patients with beryllium
sensitization is planned.
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